Valuation : Alkermes plc

Market Cap 771.21Cr 664.47Cr 629.17Cr 570.28Cr 1.07TCr 74TCr 1.08TCr 7.47TCr 2.87TCr 37TCr 2.9TCr 2.83TCr 1,18400Cr P/E 2026 *
-90.1x
P/E 2027 * 63.3x
Enterprise Value 845.6Cr 728.57Cr 689.86Cr 625.29Cr 1.17TCr 81TCr 1.18TCr 8.19TCr 3.15TCr 41TCr 3.18TCr 3.11TCr 1,29900Cr EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.31x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day-0.30%
1 week-0.28%
Current month-2.17%
1 month-6.58%
3 months+2.34%
6 months+65.54%
Current year+64.30%
1 week 44.63
Extreme 44.63
46.75
1 month 44.63
Extreme 44.63
51.66
Current year 27
Extreme 27
55.67
1 year 26.4
Extreme 26.4
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 53 01/08/2026
Director/Board Member 74 26/05/2016
Date Insider Type Main position Quantity % Market Cap. Importance
03/09/26 Sell

Compliance Officer

-2,034 0.0012%
01/09/26 Exercice

Chief Technology Officer

19,000 0.0113%
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-0.28% - - 771.21Cr
Average -0.30%
Weighted average by Cap. -0.30%

Financials

2026 *2027 *
Net sales 182.49Cr 157.23Cr 148.88Cr 134.94Cr 253.16Cr 17TCr 254.45Cr 1.77TCr 679.96Cr 8.87TCr 685.36Cr 670.33Cr 28TCr 194.48Cr 167.57Cr 158.66Cr 143.81Cr 269.8Cr 19TCr 271.17Cr 1.88TCr 724.65Cr 9.45TCr 730.41Cr 714.38Cr 30TCr
Net income -8.99Cr -7.75Cr -7.34Cr -6.65Cr -12Cr -859.05Cr -13Cr -87Cr -34Cr -437.05Cr -34Cr -33Cr -1.38TCr 12Cr 10Cr 9.81Cr 8.89Cr 17Cr 1.15TCr 17Cr 116.55Cr 45Cr 584.65Cr 45Cr 44Cr 1.85TCr
Net Debt 74Cr 64Cr 61Cr 55Cr 103.2Cr 7.11TCr 103.72Cr 720.81Cr 277.18Cr 3.62TCr 279.39Cr 273.26Cr 11TCr 67Cr 58Cr 55Cr 50Cr 93Cr 6.4TCr 93Cr 649.12Cr 249.61Cr 3.26TCr 251.6Cr 246.08Cr 10TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
11/26/11 $45.97 -0.30% 12,83,128
10/26/10 $46.11 +1.56% 11,93,903
09/26/09 $45.40 -0.20% 14,42,769
08/26/08 $45.49 -1.32% 13,55,832
04/26/04 $46.10 -1.66% 10,64,034
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
45.97USD
Average target price
56.00USD
Spread / Average Target
+21.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!